Our Vision In Action

Our platform enables discovery of high-quality, novel molecules more rapidly, at lower cost

Our world-class drug discovery team is leveraging our computational platform and massive computing power to advance our preclinical pipeline and a portfolio of programs in collaboration with leading biotech and pharmaceutical companies.

Pipeline

Program

Discovery

IND-Enabling

Clinical

Rights

Program

MALT1

Relapsed / Resistant
Non-Hodgkin's Lymphoma

IND Enabling

Program

CDC7

Hematological Cancers and
Solid Tumors

Discovery

Program

WEE1

Gynecological Cancers and
other Solid Tumors

Discovery

Rights

Program

HIF-2a

Renal Cell Carcinoma

Discovery

Program

SOS1 / KRAS

KRAS-Driven Cancers

Discovery

Program

Undisclosed

Oncology, Immunology, and
Neurology

Discovery

Rights

Collaborative Programs

We have teamed up with venture capitalists, leading academics, and biopharma companies around the globe to establish research collaborations and co-found startups. We currently have collaborative drug discovery programs with more than 10 companies.

Some of the companies include Ajax Therapeutics, Bright Angel Therapeutics, Faxian Therapeutics, Morphic Holding, Nimbus Therapeutics, Ono Pharmaceutical, Sanofi, ShouTi , Sun Pharma Advanced Research Company (SPARC), Takeda, and TB Alliance. These programs are being advanced by our collaborators in diverse therapeutic areas, including oncology, antifungals, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, neurodegenerative disease, and tuberculosis.

These collaborations have to date resulted in two FDA approved drugs and multiple programs that have advanced into clinical trials.